TL;DR
- OTC lidocaine patches contain 4% lidocaine and are marketed as nonprescription products for minor muscle and joint discomfort in adults and children 12 and older.
- The only prescription lidocaine patch with a specific FDA-approved indication is Lidoderm (5%), labeled solely for post-herpetic neuralgia — the nerve pain that can follow shingles.
- OTC lidocaine patches in patch form are not covered by the FDA's OTC External Analgesic Monograph and have not gone through the same pre-market clinical trial process as Lidoderm.
The Two Worlds of Lidocaine Patches
Walk into a pharmacy and you will find lidocaine patches in two places: on the open shelf and behind the counter with a pharmacist's assistance. What you find on the open shelf is the OTC, or over-the-counter, version. What requires a prescription is a different product entirely.
The concentration number — 4% versus 5% — is one of the smaller differences between these two categories. The larger differences involve how each product was reviewed and approved, what conditions each is labeled for, and how the dosing instructions compare.
OTC 4% Lidocaine Patches: What You Can Buy Without a Prescription
In the United States, 4% lidocaine is the maximum concentration available without a prescription. Brands you may recognize include Aspercreme with Lidocaine, Salonpas Lidocaine, Absorbine Jr., and Lidocare. MedlinePlus lists the manufacturer-labeled uses for these products as "temporary relief of minor aches and pains of muscles and joints" in areas such as the back, shoulders, arms, neck, legs, and knees. The label covers adults and children 12 years of age and older.
OTC patches typically allow one patch at a time, worn for no more than 8 hours per application, with the option to use the patch up to three times daily. Always read your specific product's Drug Facts label, because dosing details can vary by brand.
The Regulatory Picture for OTC Patches
Here is where the story gets more nuanced than most consumer guides explain.
The FDA regulates OTC drugs through two main pathways. The first is the New Drug Application, or NDA, which requires a company to submit clinical trial data and receive individual FDA approval for a specific product. The second is the OTC Monograph system — sometimes called FDA's "recipe book" — which allows products made to a standardized formula to go to market without individual NDAs, as long as they meet the monograph conditions. For an ingredient to qualify, it must meet the GRASE standard: Generally Recognized As Safe and Effective.
The FDA finalized its OTC External Analgesic Drug Products Monograph (M017) in May 2023. That monograph covers lidocaine at concentrations between 0.5% and 4% for topical use — but it explicitly states that those concentrations are "not for use in a patch, plaster, or poultice dosage form." In plain terms: creams, gels, and lotions with lidocaine have a clear monograph pathway; OTC lidocaine in patch form does not.
This does not mean OTC lidocaine patches are illegal or necessarily unsafe. They are widely sold in major pharmacy chains and retail stores. But the accurate description is that they are marketed as OTC nonprescription products under a different regulatory mechanism than the monograph — not that they are "FDA-monograph-approved" in patch form. If you want to understand exactly what regulatory basis applies to a specific brand, a pharmacist or the product's manufacturer can explain further.
Prescription 5% Lidoderm: What It Is and What It Is Approved For
Lidoderm is the brand name for the prescription lidocaine patch 5%. Each Lidoderm patch contains 700 mg of lidocaine and is designed to release the drug slowly through the skin.
Lidoderm received its approval through the NDA pathway — meaning Endo Pharmaceuticals submitted clinical trial data and the FDA reviewed and approved the product for a specific indication. That indication is post-herpetic neuralgia, or PHN. PHN is the nerve pain that can persist for months or years after a shingles infection resolves. It is a neuropathic condition, meaning it arises from abnormal nerve signaling rather than from acute tissue damage.
According to the Lidoderm FDA prescribing information, PHN is the only FDA-approved labeled indication. Any other use of Lidoderm — including for back pain, arthritis, or general muscle soreness — is off-label, meaning it is used for a purpose not listed on the FDA-approved label.
Lidoderm dosing allows up to three patches worn simultaneously, for no more than 12 hours per day, followed by a patch-free period of at least 12 hours.
A Third Option: ZTlido (1.8%)
A second prescription lidocaine patch, ZTlido, was FDA-approved on February 28, 2018. ZTlido delivers a 1.8% concentration — less than either OTC or Lidoderm. That lower number is not a sign of weaker effect. According to pharmacokinetic study data, ZTlido was designed to achieve equivalent lidocaine bioavailability to Lidoderm at a much smaller total drug load per patch (36 mg vs. 700 mg). It carries the same PHN indication as Lidoderm. ZTlido is less commonly encountered in general consumer discussions than Lidoderm but is worth knowing exists if a clinician mentions it.
Side-by-Side: Key Differences
| Feature | OTC 4% Patch | Prescription 5% Lidoderm | |---|---|---| | Lidocaine concentration | 4% | 5% | | Drug load per patch | Varies by brand | 700 mg | | Requires prescription | No | Yes | | FDA-approved indication | None via monograph in patch form | Post-herpetic neuralgia (PHN) | | Maximum patches at once | 1 (most labels) | 3 | | Maximum wear time | 8 hours | 12 hours | | Pre-market clinical trials | Not required in same way | Required via NDA process | | Labeled for | Minor muscle/joint aches | PHN nerve pain |
What the Concentration Difference Means in Practice
A higher number does not automatically mean a more effective product for your particular situation. OTC 4% patches are not approved to treat neuropathic pain, and there is no consumer-level evidence showing that 4% is meaningfully less effective than 5% for the types of minor muscle discomfort described on OTC labels.
On the other hand, Lidoderm has undergone clinical trials for PHN specifically, and those trials are what established the label claim. OTC patches have not been subject to the same pre-market clinical trial requirements and do not have individual pharmacokinetic studies published in prescribing information for each brand.
The practical takeaway is this: if a clinician has prescribed Lidoderm for your post-herpetic neuralgia, that is the right tool for that condition. If you are looking at an OTC patch for minor muscle soreness in your shoulder, the product labeling applies to that use — just understand that the product category operates under a different regulatory framework than Lidoderm.
Which Should You Choose?
For most people, the decision is made by the situation. If you have a prescription, use the prescribed product as directed. If you are self-selecting an OTC patch for minor aches in areas covered by the product label, an OTC 4% patch is the appropriate starting point.
A few situations call for a conversation with a clinician or pharmacist before you choose:
- You have nerve pain following shingles (PHN) — this requires a clinical evaluation, not an OTC patch.
- You have used OTC patches without relief for more than 7 days — the label instructs you to stop and consult a clinician if that happens.
- You are on cardiac medications or other drugs that interact with lidocaine — a pharmacist can check your medication list.
- You want to understand what specific regulatory pathway applies to the product you are considering — your pharmacist is the right resource.
When to Talk to a Clinician
If your pain is consistent with post-herpetic neuralgia — burning, electric, or stabbing nerve pain in an area where you previously had a shingles rash — consult a clinician before choosing any over-the-counter product. PHN is the only condition for which a prescription lidocaine patch has been through the FDA clinical trial and approval process. An OTC patch is not the appropriate substitute.
If you find yourself using OTC patches continuously for more than a week without improvement, your situation may have moved beyond what any OTC product can address. Most OTC product labels state to stop use and consult a clinician if symptoms persist beyond 7 days, worsen, or clear up and return. Follow that guidance — persistent or returning pain warrants a diagnosis.
If you have a documented sensitivity to lidocaine or other amide-type anesthetics, do not rely on consumer labeling alone to decide whether a product is appropriate. Speak with a clinician who can review your allergy history and advise on alternatives.
Sources
- MedlinePlus: Lidocaine Transdermal Patch
- Lidoderm 5% FDA Label (2015)
- ZTlido FDA Approval History — Drugs.com
- ZTlido vs. Lidoderm Bioequivalence Study — PMC
- FDA OTC Monograph M017 Final Administrative Order
- Enclara Pharmacia: Comparing Rx and OTC Lidocaine Patches
Last updated: 2026-05-19
The content on this site is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. If you think you are having a medical emergency, call 911 immediately.
